.png){kind=icon}
.png){kind=icon}
Return
Penetration enhancer–containing vesicles (PEVs): from deformable liposomes to barrier-modulating delivery platforms across multiple administration routes
.png){kind=icon}
PRE
AI
I
M
B
M
DOI：10.1080/17425247.2026.2662322.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Penetration enhancer–containing vesicles (PEVs) were developed as lipid-based nanocarriers integrating vesicle deformability with controlled modulation of barrier architecture to improve drug permeation and tissue deposition.
This review provides an overview of the composition, mechanism of actions and applications of PEVs. Initially introduced for dermal and transdermal delivery, PEVs have demonstrated superior performance than conventional liposomes in enhancing skin penetration of synthetic and natural bioactive. Evidence supports extension of the PEV concept to oral, mucosal, nasal, and pulmonary delivery, where permeability, stability, and epithelial interaction represent critical challenges. Particular emphasis is placed on the barrier-oriented design of PEVs, and on the possibility of tailoring penetration enhancer selection according to drug physicochemical properties and target tissues.
The literature included in this review was identified in PubMed, Scopus, and Web of Science, focusing on 2000 to 2025 and prioritizing recent studies.
PEVs should not be considered merely as improved deformable liposomes but as adaptable barrier-modulating platforms. Their future clinical translation will depend on safety assessment of penetration enhancers, scalable manufacturing strategies, and standardized pharmacokinetic and toxicological evaluation. If supported by systematic translational studies, PEVs may represent a versatile approach for the design of next-generation noninvasive drug delivery systems.
Keywords:
Biological barriers
lipid-based nanocarriers
mucosal and nasal delivery
penetration enhancers
penetration enhancer–containing vesicles
pulmonary delivery
topical and transdermal delivery
vesicle–barrier interaction
Journal
IF:
5.4
Papers:
2.3K
Citations:
1.0W
Organization
Cited Papers